Human CRP FRET-PINCER® Assay Kit, 96 well format

The hCRP FRET-PINCER® assay is ideal for the rapid screening and quantification of human C-Reactive Protein (hCRP) in biological samples. Human C-Reactive Protein (hCRP) is a calcium-dependent ligand-binding plasma protein, mainly produced by the liver. CRP concentration is a very useful nonspecific biochemical marker of inflammation. In healthy young adult volunteer donors, the median concentration of CRP in blood is 0.8 mg/L, however, during acute-phase inflammation, values may increase to more than 500 mg/L. High plasma concentration of CRP is also associated with increased risk of stroke, myocardial infarction, and other vascular diseases. The FRET-PINCER® assay is an easy and flexible way to get fast, sensitive, and consistent results.

$200.00$375.00

Description

This assay is ideal for the rapid screening and quantification of human C-Reactive Protein (hCRP) in biological samples.

Human C-Reactive Protein (hCRP) is a calcium-dependent ligand-binding plasma protein, which is composed of five identical nonglycosylated polypeptide subunits (M.W.=23,027), each containing 206 amino acid residues. The monomers are noncovalently associated in an annular configuration with cyclic pentameric symmetry. CRP is mainly produced by the liver and CRP concentration is a very useful nonspecific biochemical marker of inflammation. In healthy young adult volunteer donors, the median concentration of CRP in blood is 0.8 mg/L, however, during acute-phase inflammation, values may increase to more than 500 mg/L. High plasma concentration of CRP is also associated with increased risk of stroke, myocardial infarction, and other vascular diseases.

 

Product Applications

  1. Detect and Quantify CRP in biological samples

  2. Biomarker of acute inflammation during pre-clinical research programs for inflammatory diseases, such as rheumatoid arthritis, lupus, and vasculitis

  3. Biomarker of cardiac risk that can be used in cardiovascular pre-clinical research programs

  4. Detection of pathogen exposure

  5. High-throughput screen of drug candidates for potential adverse inflammatory effects

Human CRP FRET PINCER 96 well labeled 

Limit of Detection: 6.25 ng/ml

Assay range: 6.25 ng/ml – 400 ng/ml

CV Value: < 3.5%

Specificity: No cross-reactivity observed

Samples: Biological buffers, culture medium, serum, or plasma

Test format: 96 well plate

Assay time: 30 minutes

 

h Insulin Assay Pic

The FRET-PINCER® assay is ideally suited for the rapid, simultaneous measurement of human CRP levels in large numbers of test samples due to its speed and simplicity. It is readily adaptable to the high-throughput screening platforms currently being used in drug discovery research. In comparison to the ELISA procedure, the PINCER® assay is:

  • Easy
    Mix test sample or standard with the assay solution and incubate at ~25°C

  • Fast
    Read fluorescent signal after 30 minutes of incubation

  • Sensitive
    Assay measures hCRP with an LOD of 6.25 ng/mL.

  • Flexible
    Assay is adaptable to both low- and high-throughput screening formats

 

Pricing: The 50-well kit is a one-time trial purchase. For bulk pricing options, please contact us. For any other questions or comments, please do not hesitate to contact us. We are always happy to help!

 

Please refer to our technology pages for information on the scientific principles and technological advancements of the FRET-PINCER® assays.


 

  1. PINCER® is a registered trademark of Mediomics, LLC, St. Louis, Missouri, U.S.A. Mediomics has a worldwide, exclusive license for this assay platform from Saint Louis University, St. Louis, Missouri.

  2. The Human CRP FRET-PINCER® Fluorescence Assay kit is provided for laboratory R&D use only. This product is not approved by the U.S. Government or by the government of any other country of the world for use in clinical diagnosis of disease or treatment of disease in humans or animals.

  3. Patents allowed and pending in the U.S. and abroad.

  4. PINCER® products have been developed with support, in part, from the National Institutes of Health, through STTR Phase I and Phase II Grants.

Catalog #: CH1021-50 , CH1021-96

Protocol: 

MSDS: